{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:02:21Z","timestamp":1785402141598,"version":"3.56.0"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","award":["A2018-032"],"award-info":[{"award-number":["A2018-032"]}],"id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["A2018-032"],"award-info":[{"award-number":["A2018-032"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","award":["C2021-081"],"award-info":[{"award-number":["C2021-081"]}],"id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["C2021-081"],"award-info":[{"award-number":["C2021-081"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Anti-PD1\/-PDL1 therapy has attracted great attention in cancer therapy in recent years, but a serious problem remains that only a small portion of patients can benefit from it. In this study, we attempted to identify a molecule that is associated with anti-PD1\/-PDL1 therapeutic efficacy through proteomic profiling of plasma obtained from patients with advanced gastric cancer (AGC) receiving anti-PD1 nivolumab monotherapy. We collected peripheral blood from 91 patients with AGC before and after nivolumab treatment, and plasma was analyzed by the SomaScan v4.1 and ELISA. Relationships between the levels and patient prognosis were statistically analyzed. To evaluate antitumor effects induced by blocking the identified molecule for which high levels were significantly associated with poor prognosis, in vivo therapeutic experiments using mouse tumor models were conducted. Proteomic data revealed that the levels of 14 molecules both before and after treatment were significantly higher in patients with progressive disease (PD) than those in non-PD patients. Among them, angiopoietin-like 3 (ANGPTL3) levels were notably higher in PD patients than those in non-PD patients, and patients with high levels of ANGPTL3 either before or after treatment showed significantly worse prognosis. In mouse tumor models with increased ANGPTL3, anti-ANGPTL3 therapy significantly reduced tumor growth and synergistically enhanced anti-PD1 therapeutic efficacy. These suggest that high levels of ANGPTL3 in plasma are a significant risk factor associated with unresponsiveness to anti-PD1 treatment and poor prognosis. Targeting ANGPTL3 in the peripheral circulation may be a promising strategy to improve clinical outcomes in anti-PD1\/-PDL1 therapy for AGC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study provides valuable evidence suggesting the importance of targeting peripheral ANGPTL3 in the anti-PD1\/-PDL1 therapy for AGC and will encourage and accelerate the development of a useful biomarker to predict responders\/nonresponders to the therapy, leading to improved clinical outcomes in the treatment of gastric cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0793","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:45:38Z","timestamp":1770050738000},"page":"350-358","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4644-9404","authenticated-orcid":false,"given":"Chie","family":"Kudo-Saito","sequence":"first","affiliation":[{"name":"1Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-5227","authenticated-orcid":false,"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-9045","authenticated-orcid":false,"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01k8ej563","id-type":"ROR","asserted-by":"publisher"}],"name":"Keio University Hospital 3 Biostatistics Unit, Clinical and Translational Research Center, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-9639","authenticated-orcid":false,"given":"Hiroshi","family":"Imazeki","sequence":"additional","affiliation":[{"name":"1Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan."},{"name":"2Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7763-7999","authenticated-orcid":false,"given":"Kai","family":"Tsugaru","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01k8ej563","id-type":"ROR","asserted-by":"publisher"}],"name":"Keio University Hospital 4 Division of Gastroenterology and Hepatology, , Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-9507","authenticated-orcid":false,"given":"Naoki","family":"Takahashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03a4d7t12","id-type":"ROR","asserted-by":"publisher"}],"name":"Saitama Cancer Center 5 Department of Gastroenterology, , Saitama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9516","authenticated-orcid":false,"given":"Takeshi","family":"Kawakami","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0042ytd14","id-type":"ROR","asserted-by":"publisher"}],"name":"Shizuoka Cancer Center 6 Division of Gastrointestinal Oncology, , Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5660-0089","authenticated-orcid":false,"given":"Yusuke","family":"Amanuma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02120t614","id-type":"ROR","asserted-by":"publisher"}],"name":"Chiba Cancer Center 7 Clinical Trial Promotion Department, , Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-3859","authenticated-orcid":false,"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[{"name":"8Department of Gastrointestinal Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-5217","authenticated-orcid":false,"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-0077","authenticated-orcid":false,"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03kfmm080","id-type":"ROR","asserted-by":"publisher"}],"name":"Aichi Cancer Center 10 Department of Clinical Oncology, , Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2932-5904","authenticated-orcid":false,"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028fz3b89","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Tsukuba Hospital 11 Department of Gastroenterology, , Tsukuba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-2051","authenticated-orcid":false,"given":"Rika","family":"Kizawa","sequence":"additional","affiliation":[{"name":"12Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-743X","authenticated-orcid":false,"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03kfmm080","id-type":"ROR","asserted-by":"publisher"}],"name":"Aichi Cancer Center 10 Department of Clinical Oncology, , Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-707X","authenticated-orcid":false,"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[{"name":"2Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."},{"name":"13Department of Medical Oncology and General Medicine, IMS Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026021906265108300_bib1","first-page":"264","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026021906265108300_bib2","doi-asserted-by":"crossref","first-page":"188615","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026021906265108300_bib3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.4251\/wjgo.v12.i11.1346","article-title":"Efficacy and safety of anti-PD-1\/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: a meta-analysis","volume":"12","author":"Yang","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"2026021906265108300_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12885-023-10605-y","article-title":"Efficacy of PD-1\/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis","volume":"23","author":"Huo","year":"2023","journal-title":"BMC Cancer"},{"key":"2026021906265108300_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026021906265108300_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/cco-23-120","article-title":"How to use anti-PD-1 therapy in gastric cancer: the approach in the United States","volume":"13","author":"Ilson","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"2026021906265108300_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14789450.2019.1559062","article-title":"Cancer biomarker discovery and translation: proteomics and beyond","volume":"16","author":"Hristova","year":"2019","journal-title":"Expert Rev Proteomics"},{"key":"2026021906265108300_bib8","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.xagr.2023.100244","article-title":"Comparative predictive power of serum vs plasma proteomic signatures in feto-maternal medicine","volume":"3","author":"Espinosa","year":"2023","journal-title":"AJOG Glob Rep"},{"key":"2026021906265108300_bib9","doi-asserted-by":"crossref","first-page":"e0123566","DOI":"10.1371\/journal.pone.0123566","article-title":"Circulating carnosine dipeptidase 1 associates with weight loss and poor prognosis in gastrointestinal cancer","volume":"10","author":"Arner","year":"2015","journal-title":"PLoS One"},{"key":"2026021906265108300_bib10","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.3390\/ijms20225689","article-title":"DEK is a potential biomarker associated with malignant phenotype in gastric cancer tissues and plasma","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026021906265108300_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s12672-024-01460-9","article-title":"Application of large-scale and multicohort plasma proteomics data to discover novel causal proteins in gastric cancer","volume":"15","author":"Tang","year":"2024","journal-title":"Discov Oncol"},{"key":"2026021906265108300_bib12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12943-024-02092-x","article-title":"Identification of microenvironment features associated with primary resistance to anti-PD-1\/PD-L1 + antiangiogenesis in gastric cancer through spatial transcriptomics and plasma proteomics","volume":"23","author":"Cousin","year":"2024","journal-title":"Mol Cancer"},{"key":"2026021906265108300_bib13","doi-asserted-by":"crossref","first-page":"e010174","DOI":"10.1136\/jitc-2024-010174","article-title":"Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)","volume":"12","author":"Shoji","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026021906265108300_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ccr.2009.01.023","article-title":"Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells","volume":"15","author":"Kudo-Saito","year":"2009","journal-title":"Cancer Cell"},{"key":"2026021906265108300_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","article-title":"Angiopoietin-like 3: from discovery to therapeutic gene editing","volume":"4","author":"Wang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2026021906265108300_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/mc.23506","article-title":"Angiopoietin-like protein 3 promotes colorectal cancer progression and liver metastasis partly via the mitogen-activated protein kinase 14 pathway","volume":"62","author":"Wang","year":"2023","journal-title":"Mol Carcinog"},{"key":"2026021906265108300_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12944-024-02038-8","article-title":"Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary","volume":"23","author":"Wong Chong","year":"2024","journal-title":"Lipids Health Dis"},{"key":"2026021906265108300_bib18","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1080\/21655979.2021.2024951","article-title":"Angiopoietin-like 3 (ANGPTL3) drives cell proliferation, migration and angiogenesis in cervical cancer via binding to integrin alpha v beta 3","volume":"13","author":"Zhong","year":"2022","journal-title":"Bioengineered"},{"key":"2026021906265108300_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12672-024-00994-2","article-title":"The regulatory mechanism of m6A modification in gastric cancer","volume":"15","author":"Wu","year":"2024","journal-title":"Discov Oncol"},{"key":"2026021906265108300_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12876-023-02844-x","article-title":"METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2026021906265108300_bib21","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1002\/cam4.3100","article-title":"Mining the role of angiopoietin-like protein family in gastric cancer and seeking potential therapeutic targets by integrative bioinformatics analysis","volume":"9","author":"Tang","year":"2020","journal-title":"Cancer Med"},{"key":"2026021906265108300_bib22","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1111\/cas.15876","article-title":"Screening of novel serum biomarkers for gastric cancer in coastal populations using a protein microarray","volume":"114","author":"Yi","year":"2023","journal-title":"Cancer Sci"},{"key":"2026021906265108300_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","article-title":"ANGPTL3 as therapeutic target","volume":"32","author":"Kersten","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"2026021906265108300_bib24","doi-asserted-by":"crossref","first-page":"e18799","DOI":"10.1016\/j.heliyon.2023.e18799","article-title":"ANGPTL3 affects the metastatic potential and the susceptibility of ovarian cancer cells to natural killer cell-mediated cytotoxicity","volume":"9","author":"Wu","year":"2023","journal-title":"Heliyon"},{"key":"2026021906265108300_bib25","doi-asserted-by":"crossref","first-page":"mjad053","DOI":"10.1093\/jmcb\/mjad053","article-title":"ANGPTL3 negatively regulates IL-1\u03b2-induced NF-\u03baB activation by inhibiting the IL1R1-associated signaling complex assembly","volume":"15","author":"Zhang","year":"2024","journal-title":"J Mol Cell Biol"},{"key":"2026021906265108300_bib26","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/cancers12071791","article-title":"Interleukin-1\u03b2 and cancer","volume":"12","author":"Rebe","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026021906265108300_bib27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.4251\/wjgo.v16.i5.1676","article-title":"Interleukin-1\u03b2: friend or foe for gastrointestinal cancers","volume":"16","author":"Khawkhiaw","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"2026021906265108300_bib28","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40265-021-01516-y","article-title":"Evinacumab: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"2026021906265108300_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0793\/3732340\/crc-25-0793.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/350\/3738506\/crc-25-0793.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/2\/350\/3738506\/crc-25-0793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:27:01Z","timestamp":1771500421000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/2\/350\/774682\/ANGPTL3-in-the-Peripheral-Circulation-Is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0793","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8317581","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31369356","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369344","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369347","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369335","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369338","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369359","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369350","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369341","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369362","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369365","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31369353","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}